Boulder, Colorado – August 25, 2020 - Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be readily achievable in patients. SARS-CoV-2 is the coronavirus responsible for the Covid-19 pandemic. Based upon these…Read more
Recent Posts by admbbt
Boulder, Colorado – November 7, 2019 - Bolder BioTechnology is pleased to announce that three scientific presentations describing use of the company’s novel interleukin-11 analog BBT-059 to treat acute radiation syndrome were given at the Radiation Research Society annual meeting held November 3-6, 2019 in San Diego, CA. An invited oral presentation entitled “Pegylated IL-11…Read more
Boulder, Colorado – July 18, 2019 - Bolder BioTechnology, Inc. announced today that it has been awarded a two year Small Business Innovation Research Grant totaling $593,507 from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant is a joint research project between Bolder BioTechnology and…Read more
Boulder, Colorado – June 12, 2019- Bolder BioTechnology, Inc. announced today that its long-acting IL-11 analog, BBT-059, has received Orphan Drug designation from the Food and Drug Administration for treatment of Acute Radiation Syndrome (ARS). Orphan Drug designation is reserved for drugs that treat diseases with fewer than 200,000 patients in the United States. Orphan…Read more
Recent Comments by admbbt
No comments by admbbt yet.